Top

Published in:

Open Access 07-06-2023 | Niclosamide | Review Article

Repurposing Niclosamide as a plausible neurotherapeutic in autism spectrum disorders, targeting mitochondrial dysfunction: a strong hypothesis

Authors: Manasi Varma, Ranjana Bhandari, Anurag Kuhad

Published in: Metabolic Brain Disease | Issue 3/2024

Abstract

Autism Spectrum Disorders (ASD) are a complex set of neurodevelopmental manifestations which present in the form of social and communication deficits. Affecting a growing proportion of children worldwide, the exact pathogenesis of this disorder is not very well understood, and multiple signaling pathways have been implicated. Among them, the ERK/MAPK pathway is critical in a number of cellular processes, and the normal functioning of neuronal cells also depends on this cascade. As such, recent studies have increasingly focused on the impact this pathway has on the development of autistic symptoms. Improper ERK signaling is suspected to be involved in neurotoxicity, and the same might be implicated in autism spectrum disorders (ASD), through a variety of effects including mitochondrial dysfunction and oxidative stress. Niclosamide, an antihelminthic and anti-inflammatory agent, has shown potential in inhibiting this pathway, and countering the effects shown by its overactivity in inflammation. While it has previously been evaluated in other neurological disorders like Alzheimer’s Disease and Parkinson’s Disease, as well as various cancers by targeting ERK/MAPK, it’s efficacy in autism has not yet been evaluated. In this article, we attempt to discuss the potential role of the ERK/MAPK pathway in the pathogenesis of ASD, specifically through mitochondrial damage, before moving to the therapeutic potential of niclosamide in the disorder, mediated by the inhibition of this pathway and its detrimental effects of neuronal development.

Ahn SY, Yang JH, Kim NH, Lee K, Cha YH, Yun JS, Kang HE, Lee Y, Choi J, Kim HS, Yook J, Yong (2017) Anti-helminthic niclosamide inhibits ras-driven oncogenic transformation via activation of GSK-3. Oncotarget 8(19):31856–31863. https://doi.org/10.18632/ONCOTARGET.16255CrossRefPubMedPubMedCentral

Albert-Gascó H, Ros-Bernal F, Castillo-Gómez E, Olucha-Bordonau FE (2020) Map/erk signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. Int J Mol Sci 21(12):1–29. https://doi.org/10.3390/IJMS21124471CrossRef

Aluko OM, Lawal SA, Ijomone OM, Aschner M (2021) Perturbed MAPK signaling in ASD: impact of metal neurotoxicity. Curr Opin Toxicol 26:1–7 Elsevier B.V. https://doi.org/10.1016/j.cotox.2021.03.009CrossRefPubMedPubMedCentral

Baass PC, Di Guglielmo GM, Authier F, Posner BI, Bergeron JJM (1995) Compartmentalized signal transduction by receptor tyrosine kinases. Trends Cell Biol 5(12):465–470. https://doi.org/10.1016/S0962-8924(00)89116-3CrossRefPubMed

Balachandar V, Rajagopalan K, Jayaramayya K, Jeevanandam K, Iyer M (2021) Mitochondrial dysfunction: a hidden trigger of autism? Genes and Diseases 8(5):629–639. https://doi.org/10.1016/J.GENDIS.2020.07.002CrossRefPubMed

Barini E, Miccoli A, Tinarelli F, Mulholland K, Kadri H, Khanim F, Stojanovski L, Read KD, Burness K, Blow JJ, Mehellou Y, Muqit MMK (2018) The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson’s Disease Associated Protein Kinase PINK1. ChemBioChem 19(5):425–429. https://doi.org/10.1002/CBIC.201700500

Betancur C (2011) Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 1380:42–77. https://doi.org/10.1016/j.brainres.2010.11.078CrossRefPubMed

Chauhan A, Gu F, Essa MM, Wegiel J, Kaur K, Brown WT, Chauhan V (2011) Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem 117(2):209–220. https://doi.org/10.1111/j.1471-4159.2011.07189.xCrossRefPubMedPubMedCentral

Chen W, Mook RA, Premont RT, Wang J (2018) Niclosamide: beyond an antihelminthic drug. Cell Signal 41:89–96. https://doi.org/10.1016/J.CELLSIG.2017.04.001CrossRefPubMed

Chen MJ, Ramesha S, Weinstock LD, Gao T, Ping L, Xiao H, Dammer EB, Duong DD, Levey AI, Lah JJ, Seyfried NT, Wood LB, Rangaraju S (2019) Microglial ERK signaling is a critical regulator of pro-inflammatory immune responses in Alzheimer’s disease. BioRxiv 798215 https://doi.org/10.1101/798215

Cheng B, Morales LD, Zhang Y, Mito S, Tsin A (2017) Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line. PLoS ONE 12(9):e0184324. https://doi.org/10.1371/journal.pone.0184324CrossRefPubMedPubMedCentral

Cheung ECC, Slack RS (2004) Emerging role for ERK as a Key Regulator of neuronal apoptosis. Sci STKE 2004(251):PE45. https://doi.org/10.1126/STKE.2512004PE45CrossRefPubMed

Cobb MH, Goldsmith EJ (1995) How MAP kinases are regulated. J Biol Chem 270(25):14843–14846. https://doi.org/10.1074/jbc.270.25.14843CrossRefPubMed

Colucci-D’Amato L, Perrone-Capano C, Di Porzio U (2003) Chronic activation of ERK and neurodegenerative diseases. BioEssays 25(11):1085–1095. https://doi.org/10.1002/bies.10355CrossRefPubMed

Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15(1):49–63. https://doi.org/10.1038/NRM3722CrossRefPubMed

Dagda RK, Cherra SJ, Kulich SM, Tandon A, Park D, Chu CT (2009) Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem 284(20):13843–13855. https://doi.org/10.1074/JBC.M808515200CrossRefPubMedPubMedCentral

Farzaei MH, Tewari D, Momtaz S, Argüelles S, Nabavi SM (2018) Targeting ERK signaling pathway by polyphenols as novel therapeutic strategy for neurodegeneration. Food Chem Toxicol 120:183–195. https://doi.org/10.1016/J.FCT.2018.07.010CrossRefPubMed

Forés-Martos J, Catalá-López F, Sánchez-Valle J, Ibáñez K, Tejero H, Palma-Gudiel H, Climent J, Pancaldi V, Fañanás L, Arango C, Parellada M, Baudot A, Vogt D, Rubenstein JL, Valencia A, Tabarés-Seisdedos R (2019) Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. Mol Autism 10(1):1–16. https://doi.org/10.1186/S13229-019-0262-8/FIGURES/5CrossRef

Formstecher E, Ramos JW, Fauquet M, Calderwood DA, Hsieh JC, Canton B, Nguyen XT, Barnier JV, Camonis J, Ginsberg MH, Chneiweiss H (2001) PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell 1(2):239–250. https://doi.org/10.1016/S1534-5807(01)00035CrossRefPubMed

Frayha GJ, Smyth JD, Gobert JG, Savel J (1997) The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 28(2):273–299. https://doi.org/10.1016/S0306-3623(96)00149-8CrossRefPubMed

Fu WY, Wang X, Ip NY (2019) Targeting neuroinflammation as a therapeutic strategy for Alzheimer’s disease: mechanisms, drug candidates, and new opportunities. ACS Chem Neurosci 10(2):872–879. https://doi.org/10.1021/ACSCHEMNEURO.8B00402/SUPPL_FILE/CN8B00402_SI_001.PDFCrossRefPubMed

Gan X, Huang S, Wu L, Wang Y, Hu G, Li G, Zhang H, Yu H, Swerdlow RH, Chen JX, Yan SSD (2014) Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer’s disease cybrid cell. Biochim et Biophys Acta - Mol Basis Disease 1842(2):220–231. https://doi.org/10.1016/j.bbadis.2013.11.009CrossRef

Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C, Wong S, Hertz-Picciotto I, Tassone F, Pessah IN (2010) Mitochondrial Dysfunction in Autism. JAMAICA 303(21):2389-96. http://www.jama.com

Guiton M, Gunn-Moore FJ, Stitt TN, Yancopoulos GD, Tavare JM (1994) Identification of in vivo brain-derived neurotrophic factor-stimulated autophosphorylation sites on the TrkB receptor tyrosine kinase by site- directed mutagenesis. J Biol Chem 269(48):30370–30377. https://doi.org/10.1016/S0021-9258(18)43823-9CrossRefPubMed

Gureasko J, Galush WJ, Boykevisch S, Sondermann H, Bar-Sagi D, Groves JT, Kuriyan J (2008) Membrane-dependent signal integration by the ras activator Son of sevenless. Nat Struct Mol Biol 15(5):452–461. https://doi.org/10.1038/NSMB.1418CrossRefPubMedPubMedCentral

He K, Aizenman E (2010) ERK signaling leads to mitochondrial dysfunction in extracellular zinc-induced neurotoxicity. J Neurochem 114(2):452–461. https://doi.org/10.1111/J.1471-4159.2010.06762CrossRefPubMedPubMedCentral

Henry RJ, Ritzel RM, Barrett JP, Doran SJ, Jiao Y, Leach JB, Gregor X, Szeto L, Wu J, Stoica BA, Faden AI, David X, Loane J (2020) Neurobiology of Disease Microglial depletion with CSF1R inhibitor during chronic phase of experimental traumatic brain Injury reduces neurodegeneration and neurological deficits. J Neurosci 40(14):2960–2974. https://doi.org/10.1523/JNEUROSCI.2402-19.2020CrossRefPubMedPubMedCentral

Hirota Y, Yamashita SI, Kurihara Y, Jin X, Aihara M, Saigusa T, Kang D, Kanki T (2015) Mitophagy is primarily due to alternative autophagy and requires the MAPK1 and MAPK14 signaling pathways. Autophagy 11(2):332–343. https://doi.org/10.1080/15548627.2015.1023047CrossRefPubMedPubMedCentral

Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24:677–736. https://doi.org/10.1146/annurev.neuro.24.1.677CrossRefPubMedPubMedCentral

Huang EJ, Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72:609–642. https://doi.org/10.1146/ANNUREV.BIOCHEM.72.121801.161629CrossRefPubMed

Huang M, Zeng S, Qiu Q, Xiao Y, Shi M, Zou Y, Yang X, Xu H, Liang L (2016) Niclosamide induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol 31:45–49. https://doi.org/10.1016/J.INTIMP.2015.11.002CrossRefPubMed

Jain N, Zhang T, Fong L, Lim CP, Cao X (1998) Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene 17(21):3157–3167. http://www.stockton-press.co.uk/oncCrossRefPubMed

James SJ, Rose S, Melnyk S, Jernigan S, Blossom S, Pavliv O, Gaylor DW (2009) Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism 23(8):2374-83. https://doi.org/10.1096/fj.08-128926

Jang SG, Lee J, Hong SM, Song YS, Kim MJ, Kwok SK, Cho M La, Park SH (2021) Niclosamide suppresses the expansion of follicular helper T cells and alleviates disease severity in two murine models of lupus via STAT3. J Translational Med 19(1):86. https://doi.org/10.1186/s12967-021-02760-2CrossRef

Jang HJ, Kim YY, Lee KM, Shin JE, Yun J (2022) The PINK1 activator Niclosamide mitigates mitochondrial dysfunction and thermal hypersensitivity in a Paclitaxel-Induced Drosophila Model of Peripheral Neuropathy. 10:863. https://doi.org/10.3390/biomedicines

Jurgeit A, McDowell R, Moese S, Meldrum E, Schwendener R, Greber UF (2012) Niclosamide is a proton carrier and targets acidic Endosomes with Broad Antiviral Effects. PLoS Pathog 8(10):e1002976. https://doi.org/10.1371/JOURNAL.PPAT.1002976CrossRefPubMedPubMedCentral

Kaur J (2014) A Comprehensive Review on Metabolic Syndrome. https://doi.org/10.1155/2014/943162

Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 30(5):872–878. https://doi.org/10.1007/s00268-005-0329-sCrossRefPubMed

Kern JK, Geier DA, Sykes LK, Geier MR (2013) Evidence of neurodegeneration in autism spectrum disorder. Transl Neurodegener 2 17 http://www.translationalneurodegeneration.com/content/2/1/17

Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim et Biophys Acta - Mol Basis Disease 1802(4):396–405. https://doi.org/10.1016/J.BBADIS.2009.12.009CrossRef

Kim JS, Kim MO, Huang SW (2017) Composition for inhibiting CIP2A comprising niclosamide

Kornfeld K, Hom DB, Horvitz HR (1995) The ksr-1 gene encodes a novel protein kinase involved in ras-mediated signaling in C. elegans. Cell 83(6):903–913. https://doi.org/10.1016/0092-8674(95)90206-6CrossRefPubMed

Levitt P, Campbell DB (2009) The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest 119(4):747–754. https://doi.org/10.1172/JCI37934CrossRefPubMedPubMedCentral

Lim HS, Kim YJ, Kim BY, Park G, Jeong SJ (2018) The anti-neuroinflammatory activity of tectorigenin pretreatment via downregulated NF-κB and ERK/JNK pathways in BV-2 microglial and microglia inactivation in mice with lipopolysaccharide. Front Pharmacol 9(9):462. https://doi.org/10.3389/FPHAR.2018.00462CrossRefPubMedPubMedCentral

Liu Z, Li Y, Lv C, Wang L, Song H (2016) Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway. Biochem Biophys Res Commun 478(2):893–899. https://doi.org/10.1016/J.BBRC.2016.08.047CrossRefPubMed

Medina M, Wandosell FG, Santa-Maria Perez I, Di Primio C, Claudia Caiazza M, Ollà I, Siano G, Varisco M, Madaro G, Quercioli V, Calvello M, Cattaneo A (2019) Identification of an ERK inhibitor as a therapeutic drug against tau aggregation in a New. https://doi.org/10.3389/fncel.2019.00386. Cell-Based Assay

Minshew NJ, Goldstein G, Dombrowski SM, Panchalingam K, Pettegrew JW (1993) A preliminary 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes. Biol Psychiatry 33(11–12):762–773. https://doi.org/10.1016/0006-3223(93)90017-8CrossRefPubMed

Mitra I, Lavillaureix A, Yeh E, Traglia M, Tsang K, Bearden CE, Rauen KA, Weiss LA (2017) Reverse Pathway Genetic Approach identifies epistasis in Autism Spectrum Disorders. PLoS Genet 13(1). https://doi.org/10.1371/journal.pgen.1006516

Morin F, Kavian N, Nicco C, Cerles O, Chéreau C, Batteux F (2016) Improvement of Sclerodermatous graft-versus-host disease in mice by Niclosamide. J Invest Dermatology 136(11):2158–2167. https://doi.org/10.1016/J.JID.2016.06.624CrossRef

Muraleva NA, Kolosova NG, Stefanova NA (2021) Mek1/2-erk pathway alterations as a therapeutic target in sporadic alzheimer’s disease: a study in senescence-accelerated oxys rats. Antioxidants 10(7):1058. https://doi.org/10.3390/ANTIOX10071058CrossRefPubMedPubMedCentral

Muresan Z, Muresan V (2007) The amyloid-precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration. D Mol Biology Cell 18:3835–3844. https://doi.org/10.1091/mbc.E06CrossRef

Nisar S, Bhat AA, Masoodi T, Hashem S, Akhtar S, Ali TA, Amjad S, Chawla S, Bagga P, Frenneaux MP, Reddy R, Fakhro K, Haris M (2019) Genetics of glutamate and its receptors in autism spectrum disorder. https://doi.org/10.1038/s41380-022-01506-w

Palmieri L, Papaleo V, Porcelli V, Scarcia P, Gaita L, Sacco R, Hager J, Rousseau F, Curatolo P, Manzi B, Militerni R, Bravaccio C, Trillo S, Schneider C, Melmed R, Elia M, Lenti C, Saccani M, Pascucci T, Persico AM (2010) Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry 15(1):38–52. https://doi.org/10.1038/mp.2008.63CrossRefPubMed

Pawson T (2004) Specificity in Signal Transduction: from Phosphotyrosine-SH2 domain interactions to Complex Cellular Systems. Cell 116(2):191–203. https://doi.org/10.1016/S0092-8674(03)01077-8CrossRefPubMed

Qiu Z, Lu P, Wang K, Zhao X, Li Q, Wen J, Zhang H, Li R, Wei H, Lv Y, Zhang S, Zhang P (2020) Dexmedetomidine inhibits neuroinflammation by altering Microglial M1/M2 polarization through MAPK/ERK pathway. Neurochem Res 45:345–353. https://doi.org/10.1007/s11064-019-02922-1CrossRefPubMed

Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281–1283. https://doi.org/10.1242/jcs.00963CrossRefPubMed

Ray LB, Sturgill TW (1988) Insulin-stimulated microtubule-associated protein kinase is phosphorylated on tyrosine and threonine in vivo [serine(threonine) protein kinase/3T3-L1 adipocytes]. Proc. Natl. Acad. Sci. USA 85:3753–3757. https://www.pnas.org

Rojas DC (2014) The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. J Neural Transm 121(8):891–905. https://doi.org/10.1007/S00702-014-1216-0CrossRefPubMedPubMedCentral

Rose S, Bennuri SC, Murray KF, Buie T, Winter H, Frye RE (2017) Mitochondrial dysfunction in the gastrointestinal mucosa of children with autism: a blinded case-control study. PLoS ONE 12(10):e0186377. https://doi.org/10.1371/JOURNAL.PONE.0186377CrossRefPubMedPubMedCentral

Rossignol DA, Frye RE (2012) A review of research trends in physiological abnormalities in autism spectrum disorders: Immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 17(4):389–401. https://doi.org/10.1038/MP.2011.165CrossRefPubMed

Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biology Reviews: MMBR 68(2):320–344. https://doi.org/10.1128/MMBR.68.2.320-344.2004CrossRefPubMedPubMedCentral

Samavati L, Monick MM, Sanlioglu S, Buettner GR, Oberley LW, Hunninghake GW (2002) Mitochondrial KATP channel openers activate the ERK kinase by an oxidant-dependent mechanism. Am J Physiol - Cell Physiol 283(1 52 – 1). https://doi.org/10.1152/AJPCELL.00514.2001/ASSET/IMAGES/LARGE/H00721077009.JPEG

Schlessinger J (1988) Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci 13(11):443–447. https://doi.org/10.1016/0968-0004(88)90219-8CrossRefPubMed

Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2):211–225. https://doi.org/10.1016/S0092-8674(00)00114-8CrossRefPubMed

Siddiqui M, Elwell C, Johnson MH (2016) Mitochondrial dysfunction in Autism Spectrum Disorders. https://doi.org/10.4172/2165-7890.1000190

Su X, Maguire-Zeiss KA, Giuliano R, Priti L, Venkatesh K, Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson’s Disease. https://doi.org/10.1016/j.neurobiolaging.2007.04.006

Sun Z, Zhang Y (1999) Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber Lung Dis 79(5):319–320. https://doi.org/10.1054/TULD.1999.0212CrossRefPubMed

Tait SWG, Green DR (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11(9):621–632. https://doi.org/10.1038/NRM2952CrossRefPubMed

Tang G, Gutierrez Rios P, Kuo SH, Akman HO, Rosoklija G, Tanji K, Dwork A, Schon EA, DiMauro S, Goldman J, Sulzer D (2013) Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol Dis 54:349–361. https://doi.org/10.1016/J.NBD.2013.01.006CrossRefPubMedPubMedCentral

The Hunt for Autism Risk Genes (2018) Retrieved August 14, 2022, from https://www.simonsfoundation.org/2018/07/30/the-hunt-for-autism-risk-genes/

Tidyman WE, Rauen KA (2009) The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19(3):230–236. https://doi.org/10.1016/j.gde.2009.04.001CrossRefPubMedPubMedCentral

Townsend KJ, Zhou P, Qian L, Bieszczad CK, Lowrey CH, Yen A, Craig RW (1999) Regulation of MCL1 through a serum response factor/elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. J Biol Chem 274(3):1801–1813. https://doi.org/10.1074/JBC.274.3.1801CrossRefPubMed

Ullrich M, Weber M, Post AM, Popp S, Grein J, Zechner M, Guerrero González H, Kreis A, Schmitt AG, Üçeyler N, Lesch KP, Schuh K (2018) OCD-like behavior is caused by dysfunction of thalamo-amygdala circuits and upregulated TrkB/ERK-MAPK signaling as a result of SPRED2 deficiency. Mol Psychiatry 23(2):444–458. https://doi.org/10.1038/mp.2016.232CrossRefPubMed

Vithayathil J, Pucilowska J, Landreth GE (2018) ERK/MAPK signaling and autism spectrum disorders. Prog Brain Res 241:63–112. https://doi.org/10.1016/bs.pbr.2018.09.008CrossRefPubMed

Weissman JR, Kelley RI, Bauman ML, Cohen BH, Murray KF, Mitchell RL, Kern RL, Natowicz MR (2008) Mitochondrial disease in Autism Spectrum Disorder Patients. Cohort Anal 3(11):e3815. https://doi.org/10.1371/journal.pone.0003815CrossRef

Wieland A, Trageser D, Gogolok S, Reinartz R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klass L, Waha A, Koch P, Fimmers R, Piestsch T, Yachnis AT, Pincus DW, Steiner DA, Bristle O, Simon M, Glas M, Scheffler B (2013) Anticancer effects of niclosamide in human glioblastoma. Clin Cancer Res 19(15):4124–4136. https://doi.org/10.1158/1078-0432.CCR-12-2795CrossRefPubMed

Wilson BE, Mochon E, Boxer LM (1996) Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 16(10):5546–5556. https://doi.org/10.1128/MCB.16.10.5546CrossRefPubMedPubMedCentral

Winston LA, Hunter T (1996) Intracellular signalling: putting JAKs on the kinase MAP. Curr Biol 6(6):668–671. https://doi.org/10.1016/S0960-9822(09)00445CrossRefPubMed

Wu CS, Li YR, Chen JJW, Chen YC, Chu CL, Pan IH, Wu YS, Lin CC (2014) Antihelminthic niclosamide modulates dendritic cells activation and function. Cell Immunol 288(1–2):15–23. https://doi.org/10.1016/J.CELLIMM.2013.12.006CrossRefPubMed

Yagoda N, Von Rechenberg M, Zaganjori E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Skate I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S, Stockwell BR (2007) RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447(7146):864–868. https://doi.org/10.1038/NATURE05859CrossRefPubMedPubMedCentral

Yeh LT, Lin CW, Lu KH, Hsieh YH, Yeh CB, Yang SF, Yang JS (2022) Niclosamide suppresses Migration and Invasion of Human Osteosarcoma cells by repressing TGFBI expression via the ERK Signaling Pathway. 23(1):484. https://doi.org/10.3390/ijms23010484

Zeki Z, Al-Gareeb A (2021) Comparative study between effect of niclosamide and vitamin c on methotrexate-induced liver injury in mice. Mustansiriya Med J 20(2):55. https://doi.org/10.4103/MJ.MJ_4_21CrossRef

Zhan H, Wang M, Han P, Yu X, Wang Y, Weng W, Yuan C, Li Y, Wang T, Shao M, Sun H (2020) Niclosamide ethanolamine prevents muscle wasting by inhibiting p38 MAPK-FoxO3a activation in mice exposed to doxorubicin. Int J Clin Exp Med 13(2):440–449. www.ijcem.com/

Title: Repurposing Niclosamide as a plausible neurotherapeutic in autism spectrum disorders, targeting mitochondrial dysfunction: a strong hypothesis
Authors: Manasi Varma
Ranjana Bhandari
Anurag Kuhad
Publication date: 07-06-2023
Publisher: Springer US
Keywords: Niclosamide
Autism Spectrum Disorder
Published in: Metabolic Brain Disease / Issue 3/2024
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-023-01247-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Repurposing Niclosamide as a plausible neurotherapeutic in autism spectrum disorders, targeting mitochondrial dysfunction: a strong hypothesis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

The role of astrocytes in the glymphatic network: a narrative review

Lessons on brain edema in HE: from cellular to animal models and clinical studies

Development of novel treatments for amyotrophic lateral sclerosis

Sestrin2 can alleviate endoplasmic reticulum stress to improve traumatic brain injury by activating AMPK/mTORC1 signaling pathway

Exploring sulforaphane as neurotherapeutic: targeting Nrf2-Keap & Nf-Kb pathway crosstalk in ASD

Circ_0027446 promotes malignant development of glioblastoma by interacting with miR-346 to up-regulate PGK1